LANGHORNE, Pa. — Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.
“The acquisition of Monistat demonstrates our company’s increased presence in and dedication to the vital category of women’s health," Insight CEO Gary Downing said. "This is a very important category to us and our retail partners, and is a key part of our growth strategy going forward," he said. “This acquisition, along with e.p.t, has increased our revenues by nearly four times in the last 12 months.”
Additionally, as part of the e.p.t transaction, Insight acquired the Uristat urinary pain treatment brand and is preparing to relaunch that brand. “We are excited to bring the Uristat brand back to consumers," Downing said. "The acquisition of Monistat and e.p.t, the relaunch of Uristat, in addition to our vast portfolio, further defines our presence within OTC and the women’s health category. Women’s health is an exciting segment and we are eager to make an impact in this category.”
The Monistat brand created the vaginal antifungal category in 1974 as a pharmaceutical, and made the Rx-to-OTC crossover in 1991.
In connection with the transaction, Ontario Teachers’ Pension Plan, through its private equity group Teachers' Private Capital, has joined Swander Pace Capital as an equity investor in Insight Pharmaceuticals.